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Abstract
Introduction: Both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers were found to reduce plasma levels of 
proinflammatory cytokines. No previous study has compared their effect on the production of anti-inflammatory cytokines.
Material and methods: The study enrolled 52 patients with grade 1 and grade 2 arterial hypertension. The participants were divided into 
two groups treated with either perindopril (4 mg daily) or telmisartan (40 mg daily). Blood pressure, plasma lipids, glucose homeostasis 
markers, as well as plasma levels of uric acid, interleukins 4, 10, 13 (IL-4, IL-10, IL-13), and high sensitivity C-reactive protein (hsCRP) 
were measured at the beginning of the study and six weeks later.
Results: Both perindopril and telmisartan reduced systolic (SBP) and diastolic blood pressure (DBP). Although both agents increased 
serum levels of IL-10, this effect was more pronounced in patients treated with telmisartan. Neither telmisartan nor perindopril affected 
circulating levels of uric acid, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, IL-4, IL-13, and hsCRP. The effect 
of telmisartan on IL-10 slightly correlated with an improvement in insulin sensitivity. Treatment-induced changes in IL-10 did not cor-
relate with hypotensive properties of perindopril and telmisartan. 
Conclusions: The obtained results indicate that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers administered 
for a short period of time produce a relatively week effect on anti-inflammatory cytokines, limited to IL-10, and stronger for telmisartan 
than for perindopril. (Endokrynol Pol 2018; 69 (6): 667–674)
Key words: anti-inflammatory cytokines; angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers; arterial hypertension; 
low-grade systemic inflammation
Streszczenie
Wstęp: Zarówno inhibitory konwertazy angiotensyny, jak i antagoniści receptora dla angiotensyny II zmniejszają stężenie cytokin 
o działaniu prozapalnym. Dotychczas nie porównywano wpływu obu grup leków na poziomie cytokin o działaniu przeciwzapalnym.
Materiał i metody: Badaniem objęto populację 52 osób z nadciśnieniem tętniczym 1. i 2. stopnia. Uczestników badania przydzielono do 
dwóch grup badawczych, leczonych odpowiednio perindoprilem (4 mg dziennie) lub telmisartanem (40 mg dziennie). Ciśnienie tętnicze, 
profil lipidowy, markery gospodarki węglowodanowej, a także stężenie kwasu moczowego, interleukin 4, 10, 13 (IL-4 , IL-10, IL-13) oraz 
białka C-reaktywnego (hsCRP) oceniono na początku badania oraz 6 tygodni później.
Wyniki: Zarówno perindopril, jak i telmisartan spowodowały spadek ciśnienia tętniczego. Chociaż oba leki podwyższały stężenie IL-10, 
wpływ ten był bardziej wyrażony w grupie leczonej telmisartanem. Żaden z badanych leków nie wpływał na stężenie kwasu moczowe-
go, glukozy, cholesterolu całkowitego, cholesterolu frakcji LDL, cholesterolu frakcji HDL, triglicerydów, IL-4, IL-13 oraz hsCRP. Wpływ 
telmisartanu na stężenie IL-10 w umiarkowanym stopniu korelował z poprawą wrażliwości na insulinę, lecz nie z siłą hipotensyjnego 
działania obu ocenianych leków.
Wnioski: Uzyskane wyniki sugerują, że inhibitory konwertazy angiotensyny i antagoniści receptora dla angiotensyny II stosowane 
krótkotrwale powodują stosunkowo nieznaczny wpływ na stężenie cytokin przeciwzapalnych, ograniczony do wzrostu stężenia IL-10, 
silniej wyrażonego w przypadku stosowania telmisartanu niż perindoprilu. (Endokrynol Pol 2018; 69 (6): 667–674)
Słowa kluczowe: cytokiny przeciwzapalne; inhibitory konwertazy angiotensyny; antagoniści receptora dla angiotensyny II; nadciśnienie 
tętnicze; przewlekły stan zapalny o niewielkim nasileniu
Introduction
Arterial hypertension is regarded as the most common 
cardiovascular disease and the main risk factor for 
stroke, peripheral arterial disease, arterial aneurysms, 
and kidney disease [1, 2]. Despite affecting a large 
proportion of the population, its aetiology remains 
poorly defined [2]. In addition to established roles of 
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We also measured hsCRP levels, which are considered 
to be a highly sensitive marker of low-grade systemic 
inflammation [23].
Material and methods
Patients
The participants of the study were selected among 
adult patients (aged 20–50 years) with pharmacological-
ly-untreated European Society of Cardiology/European 
Society of Hypertension grade 1 or 2 arterial hyperten-
sion, who had been initially supervised and eventually 
treated non-pharmacologically by community-based 
healthcare providers. To be admitted to the study, pa-
tients with grade 1 arterial hypertension were required 
to have no more than two risk factors and, on the day 
of appointment, systolic blood pressure (SBP) in the 
range between 140 and 159 mm Hg and/or diastolic 
blood pressure (DBP) in the range between 90 and 
99 mm Hg, despite complying with the lifestyle modi-
fication for at least three months before the beginning 
of the study. Patients with grade 2 hypertension (SBP: 
160 and 179 mm Hg and/or DBP: 99 and 109 mm Hg) 
were included shortly after being diagnosed, and 
non-pharmacological interventions were not imple-
mented before the study onset. 
The subjects were excluded if they met at least one 
of the following criteria: grade 3 arterial hypertension, 
secondary arterial hypertension, diabetes, congestive 
heart failure, any form of coronary artery disease, stroke 
within six months preceding the study, impaired renal 
or hepatic function, malabsorption syndrome, any acute 
and chronic inflammatory processes, or autoimmune 
disorders. We also excluded patients treated with any 
hypotensive agents, glucocorticoids, or non-steroidal 
anti-inflammatory drugs, as well as with drugs known 
to interact with angiotensin-converting enzyme inhibi-
tors and angiotensin II receptor blockers.
Study design
The study was performed in accordance with the 1964 
Helsinki Declaration, and the protocol was accepted by 
the local Ethics Committee. All included patients gave 
written, informed consent to participate in the study. All 
participants were then treated with either telmisartan 
(40 mg daily; n = 26) or perindopril (4 mg; n = 26). 
Both telmisartan and perindopril were administered 
once daily in the morning for six weeks without any 
changes in dosage during the entire study period. All 
participants were also required to comply with dietary 
recommendations (total fat intake < 30% of total energy 
intake, saturated fat intake < 7% of energy consumed, 
cholesterol intake < 200 mg per day, increase in fibre 
intake to 15 g per 1000 kcal) and were encouraged to 
the vasculature, kidneys, and central nervous system, 
there is mounting evidence that arterial hypertension 
may be related to chronic low-grade inflammation [3]. 
Both innate and adaptive immune responses seem to 
play an important role in the pathogenesis of hyper-
tension [4]. Through the generation of inflammatory 
cytokines and reactive oxygen species, macrophages 
can directly impair vasculature endothelial and smooth 
muscle function, leading to vasoconstriction and re-
sultant hypertension [5]. In turn, imbalance of distinct 
functions of T-cell subsets could be an initiating event 
in the pathogenesis of hypertension [6]. Patients with 
arterial hypertension are characterised by higher levels 
of tumour necrosis factor-α (TNF-α) [7], interleukin 6 
(IL-6) [7], and high-sensitivity C-reactive protein 
(hsCRP) [8] even after adjustment for numerous con-
founding factors (age, sex, body mass index, waist-hip 
ratio, family history of hypertension, plasma lipids, 
glucose, and other inflammatory markers). Moreover, 
a proinflammatory state was found to precede blood 
pressure elevation, suggesting its causative role in the 
development of arterial hypertension [9]. 
Both angiotensin-converting enzyme (ACE) inhibi-
tors and angiotensin II receptor blockers (sartans) are 
considered as first-line treatment for arterial hyperten-
sion [10]. The clinical benefits resulting from their use 
cannot be explained exclusively by hypotensive proper-
ties but also by so-called “pleiotropic effects” [11]. ACE 
inhibitors and angiotensin II receptors blockers were 
found to exert anti-inflammatory, immunomodulatory, 
and antioxidant effects, improve the functioning of 
vascular endothelium, as well as regulate the growth 
and migration of smooth muscle cells [11–14]. Moreover, 
ACE inhibitors produce antithrombotic, profibrinolytic, 
and anti-aggregatory effects [15].
Inflammation is characterised by an interplay be-
tween pro- and anti-inflammatory cytokines [16]. The 
latter ones are a series of immune regulatory molecules 
acting mainly by the inhibition of the production of pro-
inflammatory cytokines and/or by counteracting many 
biological effects of proinflammatory cytokines [16–18]. 
Unfortunately, studies investigating pleiotropic effects 
of hypotensive agents have concentrated on their action 
on low-grade systemic inflammation and on proinflam-
matory cytokines [19, 20]. Therefore, the aim of the pres-
ent study was to compare the impact of an ACE inhibi-
tor (perindopril) and an angiotensin-receptor blocker 
(telmisartan) on serum levels of anti-inflammatory 
cytokines. Interleukin 4 (IL-4), interleukin 10 (IL-10), 
and interleukin 13 (IL-13) were selected for study be-
cause they are major anti-inflammatory cytokines [21], 
while monocytes/macrophages and T lymphocytes, 
being key components of atherosclerotic plaque, are 
regarded as a rich source of these cytokines [17, 22]. 
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take moderate to vigorous exercise for at least 30 min 
per day. Compliance with medication usage was as-
sessed at each visit by interrogation and pill count. 
Blood pressure was measured in a sitting position using 
standard cuff equipment. They were determined dur-
ing Korotkoff sounds 1 and 5. All measurements were 
made on the left arm. The values used in statistical 
analyses were the means of three measurements taken 
at intervals of at least 5 min, starting 15 min after the 
patient had sat down. 
Laboratory assays
Laboratory assays were performed at the beginning 
of the study and after six weeks of treatment. Before 
blood collection, the participants had been resting 
in a quiet room for at least 30 min in the seated posi-
tion. To avoid diurnal variations in the parameters 
studied, all blood samples were taken between 8.00 
and 9.00 a.m. after a 12-h overnight fast in a quiet, 
temperature-controlled room (24–25°C). To minimise 
analytical errors, all measurements were performed in 
duplicate within a single analytical session, and final 
results were averaged. Plasma lipids [(total cholesterol, 
low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol, and triglycerides], glu-
cose, and uric acid were measured with standard meth-
ods using commercial kits (Roche Diagnostics, Basel, 
Switzerland). Plasma levels of insulin were assessed 
by the electro-chemiluminescence method (Roche 
Diagnostics, Basel, Switzerland). Circulating levels of 
hsCRP were assessed by immunoturbidimetry (Roche 
Diagnostics, Basel, Switzerland). Plasma levels of IL-4, 
IL-10, and IL-13 were determined using commercial 
enzyme-linked immunosorbent assay kits (Diaclone, 
Besancon, France) according to the manufacturer ’s 
instructions. Insulin resistance was assessed using the 
homeostasis model assessment 1 of insulin resistance 
index (HOMA1-IR) by the following formula: insulin 
resistance = plasma insulin [mIU/L] × plasma glucose 
[mg/dL]/405. The intra- and interassay coefficients 
of variation in our laboratory were as follows: total 
cholesterol — 2.5 and 3.3%; LDL cholesterol — 2.3 and 
Table I. Baseline characteristics of patients
Tabela I. Wyjściowa charakterystyka uczestników badania
Variable Perindopril Telmisartan Difference [95% CI] 
Number of patients [n] 26 26 —
Age [years; mean (SD)] 45 (10) 49 (12) 4 [–2, 10]
Women (%) 35 31 –4 [–28, 20]
Smokers (%) 38 31 –7 [–31, 17]
BMI [kg/m2; mean (SD)] 27.8 (3.9) 28.1 (4.3) 0.3 [–2.0, 2.6]
Waist circumference [cm; mean (SD)] 93 (11) 98 (11) 5 [–1, 11]
Grade 1/grade 2 arterial hypertension (%) 15/85 19/81 4 [–17, 25]
Prediabetes (%) 50 42 –8 [–32, 16]
Metabolic syndrome (%) 42 54 12 [–14, 36]
SBP [mm Hg; mean (SD)] 149 (12) 154 (15) 5 [–3, 13]
DBP [mm Hg; mean (SD)] 90 (8) 93 (7) 3 [–1, 7]
Total cholesterol [mg/dL; mean (SD)] 230 (38) 231 (48) 1 [–23, 25]
LDL cholesterol [mg/dL; mean (SD)] 145 (37) 148 (40) 3 [–18, 24]
HDL cholesterol [mg/dL; mean (SD)] 55 (11) 53 (13) –2 [–9, 5]
Triglycerides [mg/dL; mean (SD)] 139 (107) 152 (82) 13 [–40, 66]
Glucose [mg/dL; mean (SD)] 97 (7) 101 (15) 4 [–2, 10]
HOMA1-IR [mean (SD)] 2.6 (1.1) 3.1 (1.9) 0.5 [–0.4, 1.4]
Uric acid [mg/dL; mean (SD)] 5.8 (1.4) 6.1 (1.1) 0.3 [–0.4, 1.0]
hsCRP [mg/dL; mean (SD)] 1.24 (1.76) 1.78 (1.70) 0.54 [–0.73, 1.81] 
IL-4 [pg/ml; mean (SD)] 4.47 (1.05) 4.39 (0.96) –0.08 [–0.64, 0.48] 
IL-10 [pg/ml; mean (SD)] 13.63 (2.39) 14.55 (3.25) 0.92 [–0.67, 2.51] 
IL-13 [pg/ml; mean (SD)] 34.31 (19.75) 30.38 (16.81) –3.93 [–14.14, 6.28]
SD — standard deviation; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; LDL — low density lipoprotein; HDL — high 
density lipoprotein; HOMA1-IR — homeostasis model assessment 1 of insuline resistance index; hsCRP — high sensitivity C-reactive protein; IL — interleukin;  
CI — confidence interval
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3.9%; HDL cholesterol — 2.6 and 3.6%; triglycerides 
— 3.9 and 4.9%; glucose — 2.0 and 3.4%; insulin — 4.1 
and 5.9%; uric acid — 3.7 and 4.8%; hsCRP — 3.9 and 
5.2%; IL-10 — 4.3 and 6.3%; IL-4 — 9.2 and 13.7%; and 
IL-13 — 4.8 and 14.3%.
Statistical analysis
The Shapiro-Wilk test was used to determine whether 
the data were distributed normally. To achieve ap-
proximately normal distribution, skewed variables 
(triglycerides, HOMA1-IR, hsCRP, and hormones) were 
natural log-transformed. Comparisons between the 
groups were performed using Student’s t-test for inde-
pendent samples. The differences between the means 
of variables within the same treatment group were 
analysed with Student’s paired t-test. For categorical 
variables, the c2 test was used. The clinical importance 
of the result was assessed based on the 95% confidence 
interval (CI). The relationship between the measured 
variables was calculated using Pearson’s r-tests. Differ-
ences were regarded as statistically significant if 95% 
confidence intervals did not include the null value 
and/or two-tailed p values were below 0.05.
Results
At the beginning of the study, both groups were com-
parable with respect to sex, age, smoking, body mass 
index, waist circumference, medical history, and insulin 
sensitivity, as well as to circulating levels of total choles-
terol, LDL cholesterol, HDL cholesterol, triglycerides, 
glucose, uric acid, hsCRP, IL-4, IL-10 and IL-13 (Table I). 
No serious adverse effects were reported during the 
study period, and all patients completed the study.
Expectedly, both agents administered for six weeks 
reduced SBP and DBP, with no difference between 
both agents (Table II). Telmisartan and perindopril in-
creased serum IL-10 levels but did not change glucose, 
HOMA1-IR, uric acid, total cholesterol, LDL cholesterol, 
HDL cholesterol, triglycerides, glucose, hsCRP, IL-4, 
and IL-13. Both drugs had a neutral effect on body 
mass index and waist circumference. Between-group 
comparisons showed that treatment-induced changes 
in IL-10 were more pronounced, while post-treatment 
levels of this interleukin were higher in patients treated 
with telmisartan than in patients receiving perindopril. 
Moreover, there were differences between the action 
of both drugs on HOMA1-IR. At the end of the study 
period, there were no differences between both treat-
ment arms in blood pressure, plasma lipids, glucose 
homeostasis markers, uric acid, hsCRP, IL-4, and IL-13 
(Table II).
At the beginning of the study, there were correlations 
between: a) IL-10 and SBP (r = –0.35, p < 0.05), glucose 
levels (r = –0.40, p < 0.05), and HOMA1-IR (r = –0.43, 
p < 0.001); b) IL-4 and DBP (r = –0.31, p < 0.05), as well 
as between IL-13 and LDL cholesterol levels (r = 0.35, 
p < 0.05). At the end of the study, IL-4 levels still corre-
lated with diastolic blood pressure (r = –0.46, p < 0.001). 
Treatment-induced changes in IL-10 did not correlate 
with the effect of treatment on systolic and diastolic 
blood pressure. No other correlations were observed.
Discussion
Unlike previous reports concerning proinflammatory 
cytokines [24–26], the effect of short-term perindopril 
and telmisartan treatment on anti-inflammatory cyto-
kines was, at most, moderate. The only cytokine, the 
levels of which was significantly affected by hypoten-
sive therapy, was IL-10. Interestingly, the treatment 
arms differed in the degree of rise in circulating levels 
of this cytokine, which cannot be explained by the 
hypotensive properties of both agents. In line with 
this view, perindopril and telmisartan reduced SBP 
and DBP to similar extents, post-treatment values of 
blood pressure did not differ between perindopril- and 
telmisartan-treated patients, and the treatment-induced 
increase in IL-10 did not correlate with the strength of 
hypotensive action of both drugs. IL-10 was found to 
produce a multidirectional inhibitory effect on athero-
genesis, including a decrease in matrix metalloprotein-
ase activity, pro-inflammatory cytokine release and ac-
tion, cyclooxygenase-2 expression in lipid-loaded foam 
cells, and changes in lipid metabolism in macrophages 
[27]. Considering the important role of IL-10 deficiency 
in atherogenesis and its complications, the obtained 
results seem to be clinically relevant. They suggest that 
telmisartan may be of greater benefit to patients with 
arterial hypertension than perindopril, despite the fact 
that perindopril, being a tissue-type ACE inhibitor, was 
found to exert a much stronger effect than plasma-type 
ACE inhibitors on monocyte and lymphocyte secretory 
function and on circulating levels of proinflammatory 
cytokines [24–26].
In the light of obtained results, it seems reasonable 
to assume that a more beneficial effect of telmisartan 
than of perindopril on IL-10 levels may be, at least in 
part, attributed to differences in the impact of both 
drugs on insulin sensitivity. Apart from its angiotensin 
receptor blocker activity, telmisartan was shown to act 
as a partial agonist for peroxisome proliferator-activated 
receptor-γ, which is implicated in the regulation of 
energy homeostasis [28, 29]. In our study, IL-10 was 
the only cytokine, the levels of which correlated with 
HOMA1-IR. Moreover, the effect of telmisartan, but 
not of perindopril, on IL-10 levels correlated with 
treatment-induced changes in insulin sensitivity. Inter-
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Table II. The effect of short-term perindopril and telmisartan treatment on blood pressure, body mass index, waist circumference, 
plasma lipids, uric acid, glucose homeostasis markers, low-grade systemic inflammation, and anti-inflammatory cytokine 
levels in patients with arterial hypertension
Tabela II. Wpływ krótkotrwałego leczenia perindoprilem i telmisartanem na wartość ciśnienia tętniczego, wskaźnik masy 
ciała, obwód talii, profil lipidowy, markery homeostazy węglowodanowej, jak również na stężenie kwasu moczowego, białka 
C-reaktywnego, interleukiny 4, interleukiny 10 oraz interleukiny 13 u pacjentów z nadciśnieniem tętniczym
Variable Perindopril Telmisartan Difference (95% CI)
Systolic blood pressure [mm Hg; mean (SD)]
Baseline 
After 6 months 
Change
 
149 (12) 
136 (14)#
–13 (9) 
 
154 (15)  
136 (13)#
–18 (11)
 
5 [–3, 13] 
0 [–8, 8]  
–5 [–11, 1] 
Diastolic blood pressure [mm Hg; mean (SD)]
Baseline 
After 6 months 
Change
 
90 (8) 
84 (7)#
–6 (6)
 
93 (7) 
85 (8)# 
–8 (7)
 
3 [–1, 7] 
1 [–3, 5]  
–2 [–6, 2]
Body mass index [kg/m2; mean (SD)]
Baseline 
After 6 months 
Change
 
27.8 (3.9) 
26.7 (6.5)  
–1.1 (3.5) 
 
28.1 (4.3) 
27.0 (6.7) 
–1.1 (3.2)
 
0.3 [–2.0, 2.6] 
0.3 [–3.4, 4.0] 
0.0 [–1.9, 1.9]
Waist circumference [cm; mean (SD)]
Baseline 
After 6 months 
Change
 
93 (11) 
90 (12) 
–3 (8)
 
98 (11) 
93 (11) 
-5 (9)
 
5 [–1, 11] 
3 [–4, 10] 
–2 [–7, 3]
Total cholesterol [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
230 (38) 
224 (36) 
–6 (19)
 
231 (48) 
217 (47) 
–14 (24)
 
1 [–23, 25] 
–7 [–30, 16] 
–8 [–20, 4]
LDL cholesterol [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
145 (37) 
140 (32) 
–5 (28)
 
148 (40) 
136 (42) 
–12 (30)
 
3 [–18, 24] 
–4 [–25, 17] 
–7 [–18, 4]
HDL cholesterol [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
55 (11) 
54 (10) 
–1 (8)
 
53 (13) 
56 (18) 
3 (10)
 
–2 [–9, 5] 
2 [–6, 10] 
4 [–1, 9]
Triglycerides [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
139 (107) 
138 (102) 
–1 (43)
 
152 (82) 
147 (143) 
–5 (49)
 
13 [–40, 66] 
9 [–60, 78] 
–4 [–30, 22]
Glucose [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
97 (7) 
95 (8) 
–2 (3)
 
101 (15) 
97 (12) 
–4 (6)
 
4 [–2, 10] 
2 [–4, 8] 
–2 [–6, 2]
HOMA1-IR [mean (SD)]
Baseline 
After 6 months 
Change
 
2.6 (1.1) 
2.4 (1.2) 
–0.2 (0.5)
 
3.1 (1.9) 
2.6 (1.6) 
–0.5 (0.5)
 
0.5 [–0.4, 1.4] 
0.4 [–0.4, 1.2] 
–0.3 [–0.5, –0.1]&
Uric acid [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
5.8 (1.4) 
5.7 (1.1) 
–0.1 (0.3)
 
6.1 (1.1) 
5.9 (1.0) 
–0.2 (0.4)
 
0.3 [–0.4, 1.0] 
–0.2 [–0.4, 0.8] 
–0.1 [–0.3, 0.1] 
hsCRP [mg/dL; mean (SD)]
Baseline 
After 6 months 
Change
 
1.24 (1.76) 
0.97 (1.30) 
–0.27 (2.18) 
 
1.78 (1.70) 
1.60 (1.64) 
–0.18 (0.96)
 
0.54 [–0.73, 1.81] 
0.63 [–0.19, 1.45] 
0.09 [–0.85, 1.03]
IL-4 [pg/mL; mean (SD)]
Baseline 
After 6 months 
Change
 
4.47 (1.05) 
4.08 (0.82) 
–0.39 (0.47) 
 
4.39 (0.96) 
3.89 (0.92) 
–0.50 (0.41)
 
–0.08 [–0.64, 0.48] 
–0.19 [–0.68, 0.30] 
–0.11 [–0.36, 0.14]
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estingly, insulin-resistant subjects were characterised 
by lower systemic levels of IL-10 than subjects with 
normal sensitivity to this hormone [30] and therefore 
an increase in IL-10 in our subjects, many of whom 
fulfilled the criteria of metabolic syndrome, may 
reflect in part an improvement in insulin receptor 
action. The difference in post-treatment IL-10 in both 
study arms may also be associated with stimulation of 
B1 receptor type by increased amounts of bradykinin, 
secondary to the inhibitory effect of ACE inhibitors 
on its breakdown [31]. This explanation is supported 
by the finding of higher IL-10 levels in bradykinin 
B1 receptor knock-out mice than in control wild-type 
animals, while no similar data are available for B2 re-
ceptors [32]. Finally, unlike ACE inhibitors, decreasing 
angiotensin II availability to its AT1 and AT2 receptors, 
angiotensin receptor blockers spare AT2 receptors [33], 
increasingly recognised as an integrative part of the 
protective arm of the renin-angiotensin system [34]. 
The finding that anti-inflammatory actions resulting 
from AT2 receptor stimulation were associated with 
enhanced production of IL-10 [35] seems to be in line 
with this explanation.
Unlike IL-10, short-term hypotensive therapy 
produced a neutral effect on IL-4 and IL-13 concentra-
tions. Moreover, neither at baseline nor during treat-
ment did circulating levels of IL-4 and IL-13 correlate 
with blood pressure. These findings may suggest that 
neither of the cytokines play an important role in the 
mechanisms of action of ACE inhibitors and angiotensin 
II receptor blockers. Taking into account the presence of 
correlations between IL-4 and diastolic blood pressure, 
it seems that IL-4 may participate to the development 
of hypertension rather than be involved in pleiotropic 
effects of drugs modulating renin-angiotensin-aldo-
sterone system activity. In turn, baseline levels of IL-13 
positively correlated with LDL cholesterol. Because 
in animal studies IL-13 halted the progression of ath-
erosclerosis and promoted plaque stabilisation [36], 
the obtained results suggest that IL-13 may partially 
counteract the unfavourable effect of hypercholester-
olaemia on the development and/or progression of 
atherosclerosis and its complications. Both IL-4 and 
IL-13 share a common receptor signalling pathway 
(IL-4Rα/IL-13Rα1/STAT6) [37], and therefore their ac-
tions partially overlap. Differences in observed correla-
tions may, however, be explained by specific functions 
of IL-4 and IL-13, being a consequence of engagement 
of the alternative IL-4Rα/γc and IL-13Rα2 receptors, 
and/or by differences in ligand affinity for the same 
IL-4Rα/IL-13Rα1 receptor complex [38–40].
Another interesting finding of our study was 
that neither perindopril nor telmisartan treatment 
administered for six weeks had a significant effect on 
hsCRP levels. Moreover, the impact of treatment on 
anti-inflammatory cytokines did not correlate with its 
action on hsCRP, irrespective of whether correlations 
were assessed at baseline or during treatment. The latter 
observation is in disagreement with our previous re-
ports, which showed that the changes in proinflamma-
tory cytokines were paralleled by a decrease in hsCRP 
[24–26, 41]. On the basis of the obtained results, we may 
draw two conclusions. Firstly, six weeks is a too short 
a period to reveal systemic anti-inflammatory effects 
of perindopril and telmisartan. Secondly, circulating 
levels of hsCRP do not precisely reflect the action of 
ACE inhibitors and angiotensin II receptor blockers on 
the production and metabolism of anti-inflammatory 
cytokines and/or do not contribute to their synthesis 
and release.
IL-10 [pg/mL; mean (SD)]
Baseline 
After 6 months 
Change
 
13.63 (2.39) 
15.70 (2.64)#
2.07 (1.21)
 
14.55 (3.25) 
18.50 (2.88)#
3.95 (2.45)
 
0.92 [–0.67, 2.51] 
2.80 [1.26, 4.34]* 
1.88 [0.80, 2.96]&
IL-13 [pg/mL; mean (SD)]
Baseline 
After 6 months 
Change
 
34.31 (19.75) 
30.73 (19.99) 
–3.58 (3.70)
 
30.38 (16.81) 
27.85 (16.48) 
–2.53 (2.41) 
 
–3.93 [–14.14, 6.28] 
–2.88 [–13.08, 7.32] 
1.05 [–0.69, 2.79] 
*statistically significant difference between both groups; #statistically significant difference between post-treatment and baseline values in the same group; 
&statistically significant difference between the changes in both treatment groups; SD — standard deviation; BMI — body mass index; SBP — systolic blood pressure; 
DBP — diastolic blood pressure; LDL — low density lipoprotein; HDL — high density lipoprotein; HOMA1-IR — homeostasis model assessment 1 of insuline resistance 
index; hsCRP — high sensitivity C-reactive protein; IL — interleukin; CI — confidence interval
Table II (cont.). The effect of short-term perindopril and telmisartan treatment on blood pressure, body mass index, waist 
circumference, plasma lipids, uric acid, glucose homeostasis markers, low-grade systemic inflammation, and anti-inflammatory 
cytokine levels in patients with arterial hypertension
Tabela II (kont.). Wpływ krótkotrwałego leczenia perindoprilem i telmisartanem na wartość ciśnienia tętniczego, wskaźnik 
masy ciała, obwód talii, profil lipidowy, markery homeostazy węglowodanowej, jak również na stężenie kwasu moczowego, 
białka C-reaktywnego, interleukiny 4, interleukiny 10 oraz interleukiny 13 u pacjentów z nadciśnieniem tętniczym
Variable Perindopril Telmisartan Difference (95% CI)
673
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We are aware of some limitations of this study. 
Firstly, a small number of participants and a short 
period of treatment limit the statistical significance of 
the findings. Secondly, it is difficult to answer the ques-
tion of whether the obtained results can be considered 
as a class effect of ACE inhibitors and angiotensin II 
receptor blockers, or as specific to perindopril and 
telmisartan. Thirdly, because perindopril and telmis-
artan were used in relatively small doses, it cannot be 
excluded that their effect would be stronger if they 
were given in maximal doses. Finally, it is not known 
whether the impact of perindopril and telmisartan on 
anti-inflammatory cytokines is similar in patients with 
coexisting diabetes and/or coronary artery disease, not 
included in the current study. 
Conclusions
In conclusion, although both perindopril and telmis-
artan reduced SBP and DBP in hypertensive patients, 
their action on anti-inflammatory cytokines was rela-
tively mild and limited to IL-10. The effect on IL-10, 
representing a pleiotropic action of both agents, was 
stronger for telmisartan than perindopril, and this 
finding suggests that angiotensin II receptor block-
ers may offer extra benefits in comparison with ACE 
inhibitors. Because of numerous study limitations, 
the obtained results should be supported in a larger 
clinical trial.
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